{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:35:06Z","timestamp":1792427706221,"version":"4.5.0"},"reference-count":88,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T00:00:00Z","timestamp":1559606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.drudis.2019.05.038","type":"journal-article","created":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T22:20:35Z","timestamp":1559686835000},"page":"1685-1693","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":113,"title":["Ocular gene therapies in clinical practice: viral vectors and nonviral alternatives"],"prefix":"10.1016","volume":"24","author":[{"given":"Thierry","family":"Bordet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francine","family":"Behar-Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2019.05.038_bib0005","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/nm0696-649","article-title":"Photoreceptor cell rescue in retinal degeneration (rd) mice by in vivo gene therapy","volume":"2","author":"Bennett","year":"1996","journal-title":"Nat. Med."},{"key":"10.1016\/j.drudis.2019.05.038_bib0010","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/nbt0118-6a","article-title":"FDA approves hereditary blindness gene therapy","volume":"36","author":"XXXX","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.drudis.2019.05.038_bib0015","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1056\/NEJMoa0802315","article-title":"Safety and efficacy of gene transfer for Leber\u2019s congenital amaurosis","volume":"358","author":"Maguire","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2019.05.038_bib0020","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1089\/hum.2008.107","article-title":"Treatment of Leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial","volume":"19","author":"Hauswirth","year":"2008","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.drudis.2019.05.038_bib0025","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1056\/NEJMoa0802268","article-title":"Effect of gene therapy on visual function in Leber\u2019s congenital amaurosis","volume":"358","author":"Bainbridge","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2019.05.038_bib0030","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.ophtha.2012.11.048","article-title":"Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital Amaurosis type 2","volume":"120","author":"Testa","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2019.05.038_bib0035","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1001\/archophthalmol.2011.298","article-title":"Gene therapy for Leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years","volume":"130","author":"Jacobson","year":"2012","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.drudis.2019.05.038_bib0040","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0140-6736(16)30371-3","article-title":"Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood\u2013onset blindness caused by RPE65 mutations: a follow-on phase 1 trial","volume":"388","author":"Bennett","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2019.05.038_bib0045","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002865","article-title":"AAV2 gene therapy readministration in three adults with congenital blindness","volume":"4","author":"Bennett","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.drudis.2019.05.038_bib0050","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65\u2013mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2019.05.038_bib0055","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.molmed.2018.06.006","article-title":"Seeing the light after 25 years of retinal gene therapy","volume":"24","author":"Trapani","year":"2018","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.drudis.2019.05.038_bib0060","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2174\/15665232113136660007","article-title":"Biosafety of recombinant adeno-associated virus vectors","volume":"13","author":"Dismuke","year":"2013","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.drudis.2019.05.038_bib0065","doi-asserted-by":"crossref","first-page":"6916","DOI":"10.1073\/pnas.94.13.6916","article-title":"Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus","volume":"94","author":"Flannery","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2019.05.038_bib0070","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1093\/hmg\/5.5.591","article-title":"Gene transfer into the mouse retina mediated by an adeno-associated viral vector","volume":"5","author":"Ali","year":"1996","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.drudis.2019.05.038_bib0075","first-page":"2543","article-title":"In vivo transfer of a reporter gene to the retina mediated by an adenoviral vector","volume":"35","author":"Li","year":"1994","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.drudis.2019.05.038_bib0080","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.preteyeres.2014.08.001","article-title":"Vector platforms for gene therapy of inherited retinopathies","volume":"43","author":"Trapani","year":"2014","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.drudis.2019.05.038_bib0085","doi-asserted-by":"crossref","first-page":"10319","DOI":"10.1073\/pnas.94.19.10319","article-title":"Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector","volume":"94","author":"Miyoshi","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2019.05.038_bib0090","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/sj.gt.3302485","article-title":"Lentiviral vector-mediated gene transfer in adult mouse photoreceptors is impaired by the presence of a physical barrier","volume":"12","author":"Gruter","year":"2005","journal-title":"Gene Ther."},{"key":"10.1016\/j.drudis.2019.05.038_bib0095","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.1167\/iovs.13-11871","article-title":"Transduction of photoreceptors with equine infectious anemia virus lentiviral vectors: safety and biodistribution of StarGen for Stargardt disease","volume":"54","author":"Binley","year":"2013","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.drudis.2019.05.038_bib0100","article-title":"Gene Therapy: The New Frontier for Inherited Retinal Disease","author":"Kay","year":"2017","journal-title":"Retina Specialist"},{"key":"10.1016\/j.drudis.2019.05.038_bib0105","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.ajo.2013.12.018","article-title":"Clinical utilization of anti-VEGF agents and disease monitoring in neovascular age-related macular degeneration","volume":"157","author":"Holekamp","year":"2014","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.drudis.2019.05.038_bib0110","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1097\/00006982-200410000-00002","article-title":"Risks of intravitreous injection: a comprehensive review","volume":"24","author":"Jager","year":"2004","journal-title":"Retina"},{"key":"10.1016\/j.drudis.2019.05.038_bib0115","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/14728214.2017.1362390","article-title":"Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration","volume":"22","author":"Hussain","year":"2017","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.drudis.2019.05.038_bib0120","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(17)30979-0","article-title":"Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial","volume":"390","author":"Heier","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2019.05.038_bib0125","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1089\/hum.2016.117","article-title":"Lentiviral vector gene transfer of endostatin\/angiostatin for macular degeneration (GEM) study","volume":"28","author":"Campochiaro","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.drudis.2019.05.038_bib0130","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ymthe.2018.11.003","article-title":"Preclinical evaluation of ADVM-022, a novel gene therapy approach to treating wet age-related macular degeneration","volume":"27","author":"Grishanin","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.drudis.2019.05.038_bib0135","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.preteyeres.2009.11.003","article-title":"The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited","volume":"29","author":"Anderson","year":"2010","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.drudis.2019.05.038_bib0140","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1084\/jem.170.3.637","article-title":"CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells","volume":"170","author":"Davies","year":"1989","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.drudis.2019.05.038_bib0145","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.4049\/jimmunol.144.9.3478","article-title":"The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9","volume":"144","author":"Rollins","year":"1990","journal-title":"J. Immunol."},{"key":"10.1016\/j.drudis.2019.05.038_bib0150","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/mt.2009.277","article-title":"Gene therapy for Leber\u2019s congenital amaurosis is safe and effective through 1.5 years after vector administration","volume":"18","author":"Simonelli","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.drudis.2019.05.038_bib0155","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1089\/hum.2016.111","article-title":"Evaluation of dose and safety of AAV7m8 and AAV8BP2 in the Non-human primate retina","volume":"28","author":"Ramachandran","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.drudis.2019.05.038_bib0160","doi-asserted-by":"crossref","first-page":"9933","DOI":"10.1128\/JVI.79.15.9933-9944.2005","article-title":"Packaging capacity of adeno\u2013associated virus serotypes: impact of larger genomes on infectivity and postentry steps","volume":"79","author":"Grieger","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.drudis.2019.05.038_bib0165","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ymthe.2017.11.019","article-title":"Triple vectors expand AAV transfer capacity in the retina","volume":"26","author":"Maddalena","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.drudis.2019.05.038_bib0170","article-title":"Public Summary of Opinion on Orphan Designation: Mixture of Two Adeno-Associated Viral Vectors Serotype 8 Containing the 5\u2019-Half Sequence Of Human MYO7A Gene and the 3\u2019-Half Sequence of Human MYO7A Gene For The Treatment of Usher Syndrome","author":"EMA","year":"2015","journal-title":"EMA"},{"key":"10.1016\/j.drudis.2019.05.038_bib0175","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/gt.2013.3","article-title":"Retinal gene therapy with a large MYO7A cDNA using adeno-associated virus","volume":"20","author":"Lopes","year":"2013","journal-title":"Gene Ther."},{"key":"10.1016\/j.drudis.2019.05.038_bib0180","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/emmm.201302948","article-title":"Effective delivery of large genes to the retina by dual AAV vectors","volume":"6","author":"Trapani","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.drudis.2019.05.038_bib0185","doi-asserted-by":"crossref","first-page":"E517","DOI":"10.1073\/pnas.1218933110","article-title":"Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement","volume":"110","author":"Cideciyan","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2019.05.038_bib0190","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa1412965","article-title":"Improvement and decline in vision with gene therapy in childhood blindness","volume":"372","author":"Jacobson","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2019.05.038_bib0195","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1007\/s00347-016-0306-9","article-title":"Atrophy of the macula in the context of its wet, age-related degeneration: an inescapable consequence of anti-VEGF therapy?","volume":"113","author":"Garweg","year":"2016","journal-title":"Ophthalmologe"},{"key":"10.1016\/j.drudis.2019.05.038_bib0200","article-title":"AAV Vector Manufacturing: Challenges & Opportunities in the Manufacturing of AAV Vectors Used in the Delivery of Gene Therapy Treatments","author":"Smith","year":"2017","journal-title":"Drug Dev. Deliv."},{"key":"10.1016\/j.drudis.2019.05.038_bib0205","doi-asserted-by":"crossref","first-page":"16002","DOI":"10.1038\/mtm.2016.2","article-title":"Manufacturing of recombinant adeno\u2013associated viral vectors for clinical trials","volume":"3","author":"Clement","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.drudis.2019.05.038_bib0210","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/btm2.10090","article-title":"How will the field of gene therapy survive its success?","volume":"3","author":"Kaemmerer","year":"2018","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.drudis.2019.05.038_bib0215","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1080\/17425247.2016.1201059","article-title":"Application of lipid nanoparticles to ocular drug delivery","volume":"13","author":"Battaglia","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.drudis.2019.05.038_bib0220","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3390\/jfb6020379","article-title":"Lipid nanoparticles for ocular gene delivery","volume":"6","author":"Wang","year":"2015","journal-title":"J. Funct. Biomater."},{"key":"10.1016\/j.drudis.2019.05.038_bib0225","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19092830","article-title":"Ocular Drug delivery: role of degradable polymeric nanocarriers for ophthalmic application","volume":"19","author":"Tsai","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.drudis.2019.05.038_bib0230","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/med.21509","article-title":"Gold nanoparticles in ophthalmology","volume":"39","author":"Masse","year":"2019","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.drudis.2019.05.038_bib0235","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.msec.2017.04.068","article-title":"Non\u2013viral strategies for ocular gene delivery","volume":"77","author":"Oliveira","year":"2017","journal-title":"Mater. Sci. Eng. C Mater. Biol. Appl."},{"key":"10.1016\/j.drudis.2019.05.038_bib0240","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jconrel.2015.10.007","article-title":"Non-viral therapeutic approaches to ocular diseases: an overview and future directions","volume":"219","author":"Zulliger","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.drudis.2019.05.038_bib0245","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/sj.mt.6300365","article-title":"Cell surface nucleolin serves as receptor for DNA nanoparticles composed of pegylated polylysine and DNA","volume":"16","author":"Chen","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.drudis.2019.05.038_bib0250","doi-asserted-by":"crossref","first-page":"521","DOI":"10.2217\/nnm.11.158","article-title":"Direct gene transfer with compacted DNA nanoparticles in retinal pigment epithelial cells: expression, repeat delivery and lack of toxicity","volume":"7","author":"Han","year":"2012","journal-title":"Nanomedicine"},{"key":"10.1016\/j.drudis.2019.05.038_bib0255","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1093\/hmg\/ddt013","article-title":"S\/MAR-containing DNA nanoparticles promote persistent RPE gene expression and improvement in RPE65-associated LCA","volume":"22","author":"Koirala","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.drudis.2019.05.038_bib0260","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ejpb.2014.12.028","article-title":"Nanoparticle-based technologies for retinal gene therapy","volume":"95","author":"Adijanto","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.drudis.2019.05.038_bib0265","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.2147\/IJN.S157000","article-title":"DNA nanoparticles are safe and nontoxic in non-human primate eyes","volume":"13","author":"Kelley","year":"2018","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.drudis.2019.05.038_bib0270","first-page":"692","article-title":"Single-stranded oligonucleotide-mediated in vivo gene repair in the rd1 retina","volume":"13","author":"Andrieu-Soler","year":"2007","journal-title":"Mol. Vis."},{"key":"10.1016\/j.drudis.2019.05.038_bib0275","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.exer.2008.04.009","article-title":"Non-invasive gene transfer by iontophoresis for therapy of an inherited retinal degeneration","volume":"87","author":"Souied","year":"2008","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.drudis.2019.05.038_bib0280","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.nano.2011.01.006","article-title":"Polyethylenimine-conjugated gold nanoparticles: gene transfer potential and low toxicity in the cornea","volume":"7","author":"Sharma","year":"2011","journal-title":"Nanomedicine"},{"key":"10.1016\/j.drudis.2019.05.038_bib0285","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1021\/acs.molpharmaceut.8b00207","article-title":"Current progress in electrotransfection as a nonviral method for gene delivery","volume":"15","author":"Cervia","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.drudis.2019.05.038_bib0290","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.2217\/nnm-2016-0144","article-title":"Efficient and safe gene delivery to human corneal endothelium using magnetic nanoparticles","volume":"11","author":"Czugala","year":"2016","journal-title":"Nanomedicine"},{"key":"10.1016\/j.drudis.2019.05.038_bib0295","doi-asserted-by":"crossref","first-page":"4803","DOI":"10.3892\/mmr.2015.4054","article-title":"Gene therapy for ocular diseases meditated by ultrasound and microbubbles (Review)","volume":"12","author":"Wan","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.drudis.2019.05.038_bib0300","doi-asserted-by":"crossref","first-page":"60504","DOI":"10.1117\/1.JBO.22.6.060504","article-title":"Ultrafast laser\u2013assisted spatially targeted optoporation into cortical axons and retinal cells in the eye","volume":"22","author":"Batabyal","year":"2017","journal-title":"J. Biomed. Opt."},{"key":"10.1016\/j.drudis.2019.05.038_bib0305","doi-asserted-by":"crossref","first-page":"98","DOI":"10.2174\/1566523216666160331130040","article-title":"Gene electrotransfer: a mechanistic perspective","volume":"16","author":"Rosazza","year":"2016","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.drudis.2019.05.038_bib0310","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1517\/17425247.2016.1121990","article-title":"Clinical potential of electroporation for gene therapy and DNA vaccine delivery","volume":"13","author":"Lambricht","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.drudis.2019.05.038_bib0315","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s00262-015-1724-2","article-title":"Electrochemotherapy of tumors as in situ vaccination boosted by immunogene electrotransfer","volume":"64","author":"Sersa","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.drudis.2019.05.038_bib0320","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1073\/pnas.2235688100","article-title":"Electroporation and RNA interference in the rodent retina in vivo and in vitro","volume":"101","author":"Matsuda","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2019.05.038_bib0325","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.1167\/iovs.06-0092","article-title":"Gene transfer to rabbit retina with electron avalanche transfection","volume":"47","author":"Chalberg","year":"2006","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.drudis.2019.05.038_bib0330","first-page":"2211","article-title":"Technical brief: subretinal injection and electroporation into adult mouse eyes","volume":"14","author":"Johnson","year":"2008","journal-title":"Mol. Vis."},{"key":"10.1016\/j.drudis.2019.05.038_bib0335","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1038\/mt.2011.304","article-title":"Suprachoroidal electrotransfer: a nonviral gene delivery method to transfect the choroid and the retina without detaching the retina","volume":"20","author":"Touchard","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.drudis.2019.05.038_bib0340","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0968-4328(01)00002-6","article-title":"Gene transfer into retinal ganglion cells by in vivo electroporation: a new approach","volume":"33","author":"Dezawa","year":"2002","journal-title":"Micron"},{"key":"10.1016\/j.drudis.2019.05.038_bib0345","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/978-1-4614-9632-8_15","article-title":"DNA delivery in adult mouse eyes: an update with corneal outcomes","volume":"1121","author":"Nickerson","year":"2014","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.drudis.2019.05.038_bib0350","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1096\/fj.05-4737fje","article-title":"Plasmid electrotransfer of eye ciliary muscle: principles and therapeutic efficacy using hTNF-alpha soluble receptor in uveitis","volume":"20","author":"Bloquel","year":"2006","journal-title":"FASEB J."},{"key":"10.1016\/j.drudis.2019.05.038_bib0355","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/gt.2009.43","article-title":"Effects of ciliary muscle plasmid electrotransfer of TNF-alpha soluble receptor variants in experimental uveitis","volume":"16","author":"Touchard","year":"2009","journal-title":"Gene Ther."},{"key":"10.1016\/j.drudis.2019.05.038_bib0360","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1002\/jgm.1517","article-title":"The ciliary smooth muscle electrotransfer: basic principles and potential for sustained intraocular production of therapeutic proteins","volume":"12","author":"Touchard","year":"2010","journal-title":"J. Gene Med."},{"key":"10.1016\/j.drudis.2019.05.038_bib0365","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.preteyeres.2010.04.001","article-title":"Protein delivery for retinal diseases: from basic considerations to clinical applications","volume":"29","author":"El Sanharawi","year":"2010","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.drudis.2019.05.038_bib0370","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/gt.2011.154","article-title":"Non-viral gene therapy for GDNF production in RCS rat: the crucial role of the plasmid dose","volume":"19","author":"Touchard","year":"2012","journal-title":"Gene Ther."},{"key":"10.1016\/j.drudis.2019.05.038_bib0375","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/gt.2013.36","article-title":"Long-term efficacy of ciliary muscle gene transfer of three sFlt-1 variants in a rat model of laser-induced choroidal neovascularization","volume":"20","author":"El Sanharawi","year":"2013","journal-title":"Gene Ther."},{"key":"10.1016\/j.drudis.2019.05.038_bib0380","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.freeradbiomed.2015.08.018","article-title":"Targeting iron-mediated retinal degeneration by local delivery of transferrin","volume":"89","author":"Picard","year":"2015","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.drudis.2019.05.038_bib0385","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1007\/s11095-012-0721-9","article-title":"Simulating intravitreal injections in anatomically accurate models for rabbit, monkey, and human eyes","volume":"29","author":"Missel","year":"2012","journal-title":"Pharm. Res."},{"key":"10.1016\/j.drudis.2019.05.038_bib0390","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/eye.2016.177","article-title":"Doyne lecture 2016: intraocular health and the many faces of inflammation","volume":"31","author":"Dick","year":"2017","journal-title":"Eye"},{"key":"10.1016\/j.drudis.2019.05.038_bib0395","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","article-title":"Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial","volume":"388","author":"Nguyen","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2019.05.038_bib0400","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1002\/ijc.31407","article-title":"Tumor necrosis factor-alpha inhibitors and risk of non-Hodgkin lymphoma in a cohort of adults with rheumatologic conditions","volume":"143","author":"Calip","year":"2018","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.drudis.2019.05.038_bib0405","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1167\/iovs.08-3027","article-title":"Local ocular immunomodulation resulting from electrotransfer of plasmid encoding soluble TNF receptors in the ciliary muscle","volume":"50","author":"Kowalczuk","year":"2009","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.drudis.2019.05.038_bib0410","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jconrel.2018.07.013","article-title":"Non-viral ocular gene therapy, pEYS606, for the treatment of non-infectious uveitis: Preclinical evaluation of the medicinal product","volume":"285","author":"Touchard","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.drudis.2019.05.038_bib0415","doi-asserted-by":"crossref","first-page":"e286","DOI":"10.1038\/mtna.2015.59","article-title":"Endocytosis and endosomal trafficking of DNA after gene electrotransfer in vitro","volume":"5","author":"Rosazza","year":"2016","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.drudis.2019.05.038_bib0420","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0171699","article-title":"Distinct effects of endosomal escape and inhibition of endosomal trafficking on gene delivery via electrotransfection","volume":"12","author":"Cervia","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2019.05.038_bib0425","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/978-1-4614-3209-8_88","article-title":"Episomal maintenance of S\/MAR-containing non-viral vectors for RPE-based diseases","volume":"801","author":"Koirala","year":"2014","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.drudis.2019.05.038_bib0430","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/s41591-018-0295-0","article-title":"Effect of an intravitreal antisense oligonucleotide on vision in Leber congenital amaurosis due to a photoreceptor cilium defect","volume":"25","author":"Cideciyan","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.drudis.2019.05.038_bib0435","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/eye.2012.106","article-title":"Phase 1 dose-escalation study of a siRNA targeting the RTP801 gene in age-related macular degeneration patients","volume":"26","author":"Nguyen","year":"2012","journal-title":"Eye"},{"key":"10.1016\/j.drudis.2019.05.038_bib0440","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1177\/2168479014553033","article-title":"Challenges in the development of drug\/device and biologic\/device combination products in the united states and european union: a summary from the 2013 DIA Meeting on Combination Products","volume":"49","author":"Tsourounis","year":"2015","journal-title":"Ther. Innov. Regul. Sci."}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644618304720?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644618304720?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:44:04Z","timestamp":1761223444000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644618304720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":88,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S1359644618304720"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2019.05.038","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ocular gene therapies in clinical practice: viral vectors and nonviral alternatives","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2019.05.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}